Signaling Pathway
Inezetamab is a bispecific IgG1 monoclonal antibody that targets both CD40 and mesothelin (MSLN). This dual specificity enables it to engage multiple pathways involved in immune modulation and tumor cell targeting, making it a valuable tool for research in cancer immunotherapy and related fields.
重要通知：仅供研究使用。我们不向患者销售。
| Discription | Inezetamab is a bispecific IgG1 monoclonal antibody that targets both CD40 and mesothelin (MSLN). This dual specificity enables it to engage multiple pathways involved in immune modulation and tumor cell targeting, making it a valuable tool for research in cancer immunotherapy and related fields. |
||
|---|---|---|---|
| Targets |
|
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
